High-dose cis-platinum in combination with adriamycin in the treatment of ovarian carcinoma.
Although promising potential of high dose cis-platinum in the treatment of ovarian carcinoma has been reported (6,7), a combination of adriamycin (60 mg/m2) and high dose cis-platinum (100 mg/m2) in 9 patients with advanced or recurrent ovarian carcinoma revealed no improved response compared to 13 patients receiving adriamycin (60 mg/m2) and cis-platinum (60 mg/m2). In addition to increased marrow toxicity, there is suggestion of synergism of cis-platinum to adriamycin cardiotoxicity. The efficacy of other agent/agents in combination with high dose cis-platinum should further be investigated.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D004357:Drug Synergism; D005260:Female; D006321:Heart / Q000187:drug effects; D006801:Humans; D007668:Kidney / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*
D004317:Doxorubicin; D002945:Cisplatin